

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 7 2006

Vascutek Ltd. c/o Dr. Karen Kelso Regulatory Affairs Manager Newmains Avenue Inchinnan Renfrewshire, PA4 9RR Scotland

Re: K060142

Gelweave Siena Collared Ante-Flo and Plexus Vascular Grafts with Radiopaque Markers

Regulation Number: 21 CFR 870.3460 Regulation Name: Vascular Graft Prosthesis

Regulatory Class: Class II (Two)

Product Code: DSY Dated: January 13, 2006 Received: January 19, 2006

Dear Dr. Kelso:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

onna R. Lochnes

Bram D. Zuckerman, M.D. Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

(Divi	ision Sign-Off) sion of Cardiovascular		Page 1 of
Concurre	ence of CDRH, Office of I	Device Evaluation (ODE)	
(PLEASE DO NOT WRITE NEEDED)	E BELOW THIS LINE-CO	ONTINUE ON ANOTHER	PAGE IF
Prescription Use X	AND/OR	Over-The-Counter Use (21 CFR 807 Subpart C)	<u> </u>
indications For Osc.	DISEASED VESSELS	OF THE THORACIC AGEURYSM, DISSECTION	ORTA IN
Indications For Use:	WITH RADIOPAQUE	VE SIENA COLLARED F MARKERS CEMENT OF DAMAG	
Device Name:	VASCUTEK GELWEA FLO WITH RADIOPAC	AVE SIENA COLLAREI QUE MARKERS	O ANTE-
510(k) Number (if known):	к 060142		

510(k) Number 2060142